All In Biotech

Drug Trial Radar · NCT07749716

Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Severe Alopecia Areata

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 18, 2026

Primary completion

Dec 30, 2028

Study completion Dec 30, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).

Conditions

  • Alopecia Areata

Interventions

  • Drug: VC005 tabletsDrug

    VC005 repeat administration for 24 weeks

  • VC005 tabletsDrug

    VC005 repeat administration for 24 weeks

  • VC005 placebo tabletsDrug

    VC005 placebo repeat administration for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with a Severity of Alopecia Tool (SALT) score ≤ 20Time frame: at Week 24 (W24)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Peking University People's Hospital, Beijing, Beijng

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.